Mankind Pharma shares saw a significant rise, gaining 9% in two days after Investec issued a 'buy' rating with a price target of ₹3,300 per share. This momentum continues to highlight the company’s growth potential, making it an attractive opportunity for investors looking to buy shares online.
Strong growth potential for Mankind Pharma
Investec's bullish outlook is based on Mankind Pharma’s recent acquisition of Bharat Serum and Vaccines (BSV). The firm highlighted that this acquisition, combined with Mankind’s robust execution abilities, will enhance the company’s growth trajectory, particularly in the specialty drugs and vaccines segment. This offers potential for both institutional and retail investors to buy shares online in a stock that continues to show strong upward momentum.
Mankind Pharma's stock surged to a record high of ₹2,648 today, September 23. The brokerage expects the stock to climb by 25% more, indicating that it could still offer value to those considering whether to buy shares online.
Mankind's strategic acquisition
One key reason for the surge is Mankind Pharma’s acquisition of BSV, which will help the company establish a more significant presence in niche markets. BSV’s expertise in research and development, as well as its sourcing capabilities, is seen as a major competitive advantage that could fuel future growth.
In addition, BSV’s specialisation in super-speciality drugs and under-penetrated markets like IVF will open new avenues for growth. This acquisition strengthens Mankind’s presence in the pharmaceutical sector and offers potential investors a unique opportunity to buy shares online in a company poised for further expansion.
Broader market outlook
Mankind Pharma’s success is not isolated but part of a broader trend in the pharmaceutical industry. The company’s vast distribution network and strong brand presence are expected to boost BSV’s sales in India, further bolstering its market share. This synergy between the two firms makes it an attractive choice for investors who want to diversify their portfolios by choosing to buy shares online in the healthcare sector.
Fundraising plans
Mankind Pharma’s board recently approved a fundraising of up to ₹10,000 crore through Non-Convertible Debentures and Commercial Papers. While the company hasn’t disclosed how it will allocate these funds, the capital infusion is likely to support its ambitious growth plans. For those looking to buy shares online, this move indicates the company’s intent to scale its operations and maintain its competitive edge in the long term.
Invest safely
Mankind Pharma’s recent performance, supported by strategic acquisitions and strong market fundamentals, makes it a compelling option for investors to buy shares online. With a target price of ₹3,300, the stock offers potential upside, and its recent gains highlight the market's confidence in its future growth prospects. As the company continues to expand its presence in speciality pharmaceuticals, Mankind Pharma remains a stock worth watching for long-term investors.
For android only